Bristol-Myers Squibb Collaboration (Tables)

3 Months Ended

Mar. 31, 2023

Bristol-Myers Squibb Collaboration

Schedule of transaction price unsatisfied

			Cumulative collaboration		Deferred
Performance obligations:	Transaction price		revenue recognized		collaboration revenue
Option rights	$	109,164	$	-	$	109,164
Research and development services		14,023		(6,919)		7,104
Total		123,187		(6,919)		116,268
Less current portion of deferred revenue		-		-		(6,500)
Total long-term deferred revenue	$	123,187	$	(6,919)	$	109,768